Drug-Related Morbidity and Mortality: A Cost-of-Illness Model

Archives of Internal Medicine

Volumn 155, Issue 18, 1995, Pages 1949-1956

  Johnson, Jeffrey A ^a   Bootman, J Lyle ^a  

^a UNIVERSITY OF ARIZONA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONSERVATIVE TREATMENT; DISEASE ASSOCIATION; DRUG COST; DRUG INDUCED DISEASE; HEALTH CARE ORGANIZATION; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; MORBIDITY; MORTALITY; PATIENT COMPLIANCE; PRIORITY JOURNAL;

COST OF ILLNESS; DISEASE; HEALTH CARE COSTS; HUMAN; MODELS, THEORETICAL; MORTALITY; OUTCOME ASSESSMENT (HEALTH CARE); PHARMACEUTICAL PREPARATIONS; SUPPORT, NON-U.S. GOV'T; TREATMENT FAILURE; UNITED STATES;

EID: 0029130580     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinte.1995.00430180043006     Document Type: Article

References (52)

1. Hepler CD, Strand LM. Opportunities and responsibilities in pharmaceutical care. Am J Hosp Pharm. 1990;47:533-543.
2. Strand LM, Cipolle R, Morley PC. Drug-related problems: their structure and function. Drug Intell Clin Pharm. 1990;24:1093-1097.
3. Manasse HR Jr. Medication use in an imperfect world, I: drug misadventuring as an issue of public policy. Am J Hosp Pharm. 1989;46:929-944.
4. Manasse HR Jr. Medication use in an imperfect world, II: drug misadventuring as an issue of public policy. Am J Hosp Pharm. 1989;46:1141-1152.
5. Talley RB, Laventurier MF. Drug-induced illness. JAMA. 1974;229:1043.
6. The Case for America's Pharmaceutical Research Companies. Washington, DC: Pharmaceutical Research and Manufacturers of America; 1994.
7. Smith DL. The effect of patient noncompliance on health care costs. Med Interface. April 1993:74.
8. Sullivan SD, Kreling DH, Hazlet TK. Noncompliance with medication regimens and subsequent hospitalization: a literature analysis and cost of hospitalization estimate. J Res Pharm Econ. 1990;2:19-33.
9. Einarson TR. Drug-related hospital admissions. Ann Pharmacother. 1993;27: 832-840.
10. Col N, Fanale JE, Kronholm P. The role of medication noncompliance and adverse drug reactions in hospitalizations of the elderly. Arch Intern Med. 1990; 150:841-845.
11. McKenney JM, Harrison WL. Drug-related hospital admissions. Am J Hosp Pharm. 1976;33:792-795.
12. Ives TJ, Bentz EJ, Gwyther RE. Drug-related admissions to a family medicine service. Arch Intern Med. 1987;147:1117-1120.
13. Bergman U, Wiholm BE. Drug-related problems causing admissions to a medical clinic. Eur J Clin Pharmacol. 1981;20:193-200.
14. Grymonpre RB, Mitenko PA, Sitar DS, Aoki FY, Montgomery PR. Drug-associated hospital admissions in older medical patients. J Am Geriatr Soc. 1988;36:1092-1098.
15. Noncompliance With Medications: An Economic Tragedy With Important Implications for Health Care Reform. Baltimore, Md: The Task Force for Compliance; 1993.
16. La Piana Simonsen L. What are pharmacists dispensing most often? top 200 drugs of 1992. Pharm Times. April 1993:29-44.
17. 1992 Physicians Fee Guide. Augusta, Ga: HealthCare Consultants Inc; 1992.
18. Borgsdorf LR, Miano JS, Knapp KN. Pharmacist-managed medication review in a managed care system. Am J Hosp Pharm. 1994;51:772-777.
19. AHA Hospital Statistics, 1992-93 Edition. Chicago, III: American Hospital Association; 1994.
20. Nursing home utilization by current residents: United States, 1985. Vital Health Stat 13. 1989;NO. 102:39.
21. Discharges from nursing homes: 1985 National Nursing Home Survey. Vital Health Stat 13. 1990;No. 103:29.
22. Barr JT, Schumacher GE. Decision analysis and pharmacoeconomic evaluations. In: Bootman JL, Townsend RJ, McGhan WF, eds. Principles of Pharmacoeconomics. Cincinnati, Ohio: Harvey Whitney Books; 1991:113-133.
23. Decision Analysis by TreeAge: DATA for Windows, v2.5 Users Manual. Boston, Mass: TreeAge Software Inc; 1994.
24. Schappert SM. National Ambulatory Medical Care Survey: 1991 Summary. Hyattsville, Md: National Center for Health Statistics; 1993;No. 230.
25. Briggs A, Schulpher M, Buxton M. Uncertainty in the economic evaluation of health care technologies: the role of sensitivity analysis. Health Econ. 1994;3: 95-104.
26. McCaig LF. National Hospital Ambulatory Medical Care Survey: 1992 Emergency Department Summary. Hyattsville, Md: National Center for Health Statistics; 1994;No. 245.
27. Wolf AM, Colditz GA. The cost of obesity: the US perspective. Pharmaco Economics. 1994;5(suppl 1):34-37.
28. Costs of Diabetes. Alexandria, Va: American Diabetes Association; 1993.
29. Costs of Cardiovascular Diseases. Dallas, Tex: American Heart Association; 1993.
30. Rice DP, Hodgson TA, Kopstein AN. The economic costs of illness: a replication and update. Health Care Financ Rev. 1985;7:61-80.
31. Hodgson TA, Meiners MR. Cost-of-illness methodology: a guide to current practices and procedures. Milbank O. 1982;60:429-462.
32. Drummond MF. Cost-of-illness studies: a major headache. PharmacoEconomics. 1992;2:1-4.
33. Shiell A, Gerard K, Donaldson C. Cost of illness studies: an aid to decision-making? Health Policy. 1987;8:317-323.
34. Davey PJ, Leeder SR. The cost of migraine: more than just a headache? PharmacoEconomics. 1992;2:5-7.
35. Lakshmanan MC, Hershey CO, Breslau D. Hospital admissions caused by iatrogenic disease. Arch Intern Med. 1986;146:1931-1934.
36. Montamat SC, Cusack BJ, Vestal RE. Management of drug therapy in the elderly. N Engl J Med. 1989;321:303-309.
37. American Pharmaceutical Association. An APhA White Paper on the Role of the Pharmicist in Comprehensive Medication Use Management: The Delivery of Pharmaceutical Care. Washington, DC: American Pharmaceutical Association; 1992.
38. ASHP statement on pharmaceutical care. Am J Hosp Pharm. 1993;50:1720-1723.
39. Coalition for Consumer Access to Pharmaceutical Care. ACCP Report. 1993; 13:5-8.
40. Implementing pharmaceutical care. Proceedings of an invitational conference conducted by the American Society of Hospital Pharmacists and the ASHP Research and Education Foundation, March 12-15,1993, San Antonio, Texas. Am J Hosp Pharm. 1993;50:1585-1656.
41. MacKeigan LD, Bootman JL. A review of cost-benefit and cost-effectiveness analyses of clinical pharmacy services. J Pharm Market Manage. 1988;2:63-84.
42. Willett MS, Bertch KE, Rich DS, Ereshefsky LE. Prospectus on the economic value of clinical pharmacy services. Pharmacotherapy. 1989;9:45-56.
43. Britton ML, Lurvey PL. Impact of medication profile review on prescribing in a general medicine clinic. Am J Hosp Pharm. 1991;48:265-270.
44. Taylor JT, Kathman MS. Documentation of cost savings from decentralized clinical pharmacy services at a community hospital. Am J Hosp Pharm. 1991; 48:1467-1470.
45. Haig GM, Kiser LA. Effect of pharmacist participation on a medical team on costs, charges, and length of stay. Am J Hosp Pharm. 1991;48:1457-1462.
46. Lobas NH, Lepinski PW, Abramowitz PW. Effects of pharmaceutical care on medication cost and quality of care in an ambulatory-care clinic. Am J Hosp Pharm. 1992;49:1681-1688.
47. Torok N, Brown G. The economic impact of clinical pharmacists' unsolicited recommendations. Hosp Pharm. 1992;27:1052-1060.
48. Kimberlin CL, Berardo DH, Pendergast JF, McKenzie LC. Effects of an education program for community pharmacists on detecting drug-related problems in elderly patients. Med Care. 1993;31:451-468.
49. Miller SW, Warnock R, Marshall LL, Blankenship G. Cost savings and reduction of medication-related problems as a result of consultant pharmacy intervention. Consult Pharm. 1993;8:1265-1272.
50. Hatoum HT, Hutchinson RA, Witte KW, Newby GP. Evaluation of the contribution of clinical pharmacists: inpatient care and cost reduction. Drug Intell Clin Pharm. 1988;22:252-259.
51. Bjornson DC, Hiner WO, Potyk RP, et al. Effect of pharmacists on health care outcomes in hospitalized patients. Am J Hosp Pharm. 1993;50:1875-1884.
52. Dukes MNG. Economic costs of adverse drug reactions. PharmacoEconomics. 1992;1:153-154.